Singapore markets closed
Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,655.24 +153.68 (+0.23%) CMC Crypto 200
1,424.10 -4.47 (-0.31%)
SANA Jun 2024 12.500 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 12:41PM EDT
| Previous close | 4.8200 |
| Open | 4.8200 |
| Bid | 4.5000 |
| Ask | 6.0000 |
| Strike | 12.50 |
| Expiry date | 2024-06-21 |
| Day's range | 4.8200 - 4.8200 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireSana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions
Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice Additional proof-of-concept for the advancement of SC379, Sana’s pluripotent stem cell-derived glial progenitor cell product candidate SEATTLE, May 21, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today highlighted that Nature Biotechnology has published a paper titled “You
Simply Wall St.Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GuruFocus.com
Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results
Aligns with Analyst Projections Amidst Strategic Clinical Advancements
© 2024 Yahoo. All rights reserved.